Limits...
Association between BACH2 expression and clinical prognosis in diffuse large B-cell lymphoma.

Ichikawa S, Fukuhara N, Katsushima H, Takahashi T, Yamamoto J, Yokoyama H, Sasaki O, Fukuhara O, Nomura J, Ishizawa K, Ichinohasama R, Muto A, Igarashi K, Harigae H - Cancer Sci. (2014)

Bottom Line: BACH2, a B cell-specific transcriptional repressor, plays a significant role in B cell maturation.There were no significant differences between the two groups with regard to clinical characteristics and outcomes.In cases with high BACH2 expression in GCB and non-GCB groups, the 3-year overall survival (OS) rate was significantly shorter than that with low expression (71.7% vs 91.3%, P = 0.0256).

View Article: PubMed Central - PubMed

Affiliation: Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan.

Show MeSH

Related in: MedlinePlus

Survival analyses of the patients in MYC+ group. Overall survival (a) and progression-free survival (b) in association with BACH2 expression levels.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4317811&req=5

fig04: Survival analyses of the patients in MYC+ group. Overall survival (a) and progression-free survival (b) in association with BACH2 expression levels.

Mentions: All cases were treated with rituximab-containing chemotherapy, and in two cases, intensive chemotherapy was performed, taking into consideration the poor prognosis of MYC+ DLBCL.(2,3) The MYC+ group showed poor prognosis; 3-year OS and PFS rates were 35.0% and 33.7%, respectively (Fig. 4).


Association between BACH2 expression and clinical prognosis in diffuse large B-cell lymphoma.

Ichikawa S, Fukuhara N, Katsushima H, Takahashi T, Yamamoto J, Yokoyama H, Sasaki O, Fukuhara O, Nomura J, Ishizawa K, Ichinohasama R, Muto A, Igarashi K, Harigae H - Cancer Sci. (2014)

Survival analyses of the patients in MYC+ group. Overall survival (a) and progression-free survival (b) in association with BACH2 expression levels.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4317811&req=5

fig04: Survival analyses of the patients in MYC+ group. Overall survival (a) and progression-free survival (b) in association with BACH2 expression levels.
Mentions: All cases were treated with rituximab-containing chemotherapy, and in two cases, intensive chemotherapy was performed, taking into consideration the poor prognosis of MYC+ DLBCL.(2,3) The MYC+ group showed poor prognosis; 3-year OS and PFS rates were 35.0% and 33.7%, respectively (Fig. 4).

Bottom Line: BACH2, a B cell-specific transcriptional repressor, plays a significant role in B cell maturation.There were no significant differences between the two groups with regard to clinical characteristics and outcomes.In cases with high BACH2 expression in GCB and non-GCB groups, the 3-year overall survival (OS) rate was significantly shorter than that with low expression (71.7% vs 91.3%, P = 0.0256).

View Article: PubMed Central - PubMed

Affiliation: Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan.

Show MeSH
Related in: MedlinePlus